<DOC>
	<DOCNO>NCT01791049</DOCNO>
	<brief_summary>TD-1607 , administer intravenously single dos , investigate healthy subject assess tolerability , safety , pharmacokinetics .</brief_summary>
	<brief_title>TD-1607 SAD Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<criteria>Subject healthy nonsmoking male female nonchild bear potential 18 50 year old , inclusive , Screening . Females consider nonchildbearing potential hysterectomy tubal ligation postmenopausal ( amenorrheic least 2 year ) folliclestimulating hormone ( FSH ) level &gt; 20 IU/L . Subject body mass index ( BMI ) 19 30 kg/m2 , inclusive , weigh least 50 kg Subject evidence history clinically significant allergic ( except untreated , asymptomatic seasonal allergy time dose ) , hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease . Subject history allergy hypersensitivity glycopeptide ( e.g. , vancomycin ) , penicillin , cephalosporin antibiotic . Subject participate another clinical trial investigational drug ( medical device ) within 60 day ( 5 halflives , whichever long ) prior Screening currently participate another trial investigational drug ( medical device ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Gram-positive</keyword>
	<keyword>Infections</keyword>
	<keyword>Bacterial infection</keyword>
</DOC>